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 ABSTRACT
Introduction: Vascular access (VA) for hemodialysis (HD) is the lifeline for End Stage Renal Disease (ESRD) 
patients. Long-term HD patients often have exhaustion of their venous patrimony  for an autologous VA construc-
tion and, sometimes, even for a central venous catheter (CVC) placement. 
Case report: We describe the case of a 43-year-old woman with ESRD due to lupus nephritis, on maintenance 
HD since 2009. She also had secondary antiphospholipid syndrome and was chronically anticoagulated. Never-
theless, the patient had multiorgan thrombotic events (without sequelae) and several episodes of irreversible 
thrombosis of arteriovenous fistulas. Her HD course was also marked by multiple severe CVC infections, at dif-
ferent locations; a hemoperitoneum during cholecystectomy, and an immediate thrombosis of the renal artery 
of a kidney transplant. She was admitted to our hospital after an irreversible dysfunction of a right jugular CVC, 
with documentation of thrombosis of the superior and inferior vena cava. Exhaustion of the venous patrimony 
for HD was assumed and it was decided to make an arterio-arterial graft (AAG) of early cannulation. The first 
cannulation of the AAG was performed two days after surgical intervention, with no complications. The patient 
performed a twelve hour per week HD treatment with good efficiency.
Conclusion: AAG is an alternative for HD patients who have exhausted all their venous patrimony and it can 
be considered prior to the placement of a CVC as their sole remaining vascular access.  
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 INTRODUCTION
Worldwide, approximately 10% of the population 
has chronic kidney disease (CKD) and about 1.5 million 
require hemodialysis (HD)1.
The prevalence of ESRD patients requiring renal 
replacement therapy (RRT) is continuously increasing 
and is expected to reach 5.4 million worldwide by 20301. 
Most patients are treated with HD, which in most coun-
tries exceeds 60% of the prevalent ESRD population2. 
Vascular access (VA) for hemodialysis is the lifeline 
for ESRD patients and arteriovenous fistula (AVF) is the 
preferred VA since it is associated with less complica-
tions. However, long-term HD patients often require 
multiple VA interventions. In Europe over 25% of all 
hospitalizations observed in ESRD patients are related 
with the construction and maintenance of a patent HD 
VA3. 
When all the venous capital of an HD patient is 
exhausted, the use of an arterial access for HD may be 
300    Port J Nephrol Hypert 2018; 32(3): 299-304
a viable option and, in fact, the use of an artery as a 
permanent VA is not a new procedure. 
In this article we describe the clinical case of a patient 
with ESRD in HD treatment with venous capital exhaus-
tion, including for central venous catheter (CVC) place-
ment, for whom our team first arterial brachio-brachial 
graft of early cannulation was constructed.
 CASE REPORT 
We describe the case of a 43-year-old woman with 
ESRD due to lupus nephritis (LN) on maintenance HD 
since 2009. She was diagnosed with systemic lupus 
erythematous (SLE) in 1993 when she was admitted 
at our hospital with a severe presentation of the dis-
ease, with cutaneous, haematological, hepatic, renal 
and pulmonary involvement. Immunosuppressive 
therapy with cyclophosphamide and corticosteroids 
was started with favorable clinical evolution. Poste-
riorly, she was also diagnosed with secondary 
antiphospholipid syndrome (APS) and despite the 
treatment with hypocoagulation she had several 
thrombotic events (cerebellar infarcts, pulmonary 
thromboembolism) without neurological deficits or 
other sequelae. 
She evolved with progressive decline of renal func-
tion and severe arterial hypertension requiring the 
initiation of RRT by a tunneled CVC in the right internal 
jugular vein (RIJV) in February of 2008. Despite the 
close follow-up in our Vascular Access Consultation 
(VAC) and the multidisciplinary approach by Nephrology 
and Vascular Surgery, a complex path of vascular accesses 
followed (Fig.1). In 2008 a left brachiocephalic AVF was 
constructed, via which the patient began HD. However, 
she had a thrombosis without recovery in 2009 and 
this access was abandoned. This was followed by a 
complex course of multiple CVCs, with different loca-
tions and recurrent infectious complications. A new 
autologous VA (right brachiobasilic AVF) was construct-
ed, but it also irreversibly thrombosed, and therefore, 
had to be abandoned. The total absence of venous 
patrimony compatible with the construction of an 
autologous VA in the upper limbs was confirmed after 
a new VAC evaluation. 
In 2010 the patient had an acute lithiasic cholecystitis 
and underwent a laparoscopic cholecystectomy. Nev-
ertheless, it was complicated with the hemoperitoneum 
requiring posterior laparotomy. 
The patient was submitted to a deceased donor kid-
ney transplant in 2011 with immediate thrombosis of 
the renal artery, and the kidney graft had to be removed. 
In February of 2018 the patient had an infectious 
complication of the right femoral CVC (abscess of the 
tunnel that fistulized to the skin), and was referred by 
the HD center to our hospital to remove it and place 
a new one. Given the previous trajectory, it was decided 
to try to place, once again, an echo-guided and 
Ana Castro, Paulo Almeida, Filipa Silva, Duarte Rego, Joana Tavares, Josefina Santos,  
Fernanda Silva, José Alexandre Queirós, António Cabrita, Rui Almeida
Figure 1
Vascular access temporal plan.
AVF: arteriovenous fistula; CVC: Central Venous Catheter; LBC: Left Brachiocephalic; 
RBB: Right Brachiobasilic; LIJV: Left Internal Jugular Vein; RFV: Right Femoral Vein; RIJV: 
Right Internal Jugular Vein; VA: Vascular Access
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radioscopically controled with contrast infusion CVC. 
A 19cm long-term catheter Cannon® II from Arrow with 
15Fr was placed in the RIJV. Although the CVC progres-
sion was very difficult to perform, it was considered, 
at that point, the last feasible VA for the patient (Fig.2). 
A first HD treatment was performed at the hospital, 
with no complications. 
After three HD treatments the CVC presented with 
irreversible dysfunction, probably due to its location. 
The patient was hospitalized for study and therapeutic 
orientation. Conservative therapy for CKD was imme-
diately started and patient clinical and analytical sur-
veillance was performed daily. The need for HD access 
was urgent.
A computed tomography angiography (CTA) of the 
thorax and abdomen was performed to characterize 
the entire vasculature, revealing that the CVC was intro-
duced into the right internal jugular vein , the distal tip 
of which was in the most distal region of the superior 
vena cava (Fig.2). The entire upper vena cava had a 
thrombus around the catheter, without identification 
of the vessel wall or lumen. Upstream, the brachioce-
phalic venous trunks were permeable. An important 
collateral circulation in the thoracic wall associated with 
the chronic superior vena cava thrombosis was seen. 
Surprisingly, it was also observed that the inferior vena 
cava was also completely obstructed, only permeable 
above the confluence of the suprahepatic veins. 
Taking all these findings into account, we considered 
that the patient had exhaustion of the venous patri-
mony compatible with a vascular access for HD.
In this way, the clinical case was discussed with the 
Peritoneal Dialysis (PD) Unit to consider the possibility 
of performing PD. All the hospitalizations and surgical 
interventions related to the previous cholecystectomy, 
renal transplantation and all the intra-abdominal haem-
orrhagic/thrombotic complications that followed were 
carefully reviewed. It was concluded that after all epi-
sodes of intra-abdominal bleeding and laparotomies 
(with risk of associated adhesions), the technique had 
only a small chance of sucess.
After a multidisciplinary – Nephrology and Vascular 
Surgery – re-discussion of the patient, and considering 
the preservation of the thoracic arterial patrimony, the 
construction of an arterio-arterial graft (AAG) of early 
cannulation was proposed. A brachio-brachial (with 
end-to-end anastomosis) loop, using a 6 mm graft, was 
implanted in the left upper limb (Fig.3.1). At the end 
of the surgery the AAG pulse was present and the bra-
chial pulse was also patent. No complications were 
reported. 
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Figure 2
Imaging evaluation of the patient. Fig. 2.1: Radioscopic evaluation of the CVC in the RIJV; Fig. 2.2: 
Computed Tomography Angiography showing a thrombus around the CVC in superior vena cava; Fig. 
2.3: Inferior vena cava thrombosis.
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Some particularities in the management of this type 
of graft were reviewed by the hemodialysis team: the 
puncture is in ladder, to prevent the creation of false 
aneurysms since there is very high venous pressure; it 
is not possible to perform hemodiafiltration since the 
inflow is made into the arterial circuit and would induce 
ischemia; the administration of drugs in the graft is 
contraindicated; more prolonged hemostasis time; Qb 
is limited by venous pressure, so in heavier patients an 
adequate dialysis dose will only be possible with 4 
dialysis sessions or 3 long sessions. 
The first cannulation was performed by an experi-
enced HD nurse two days after the procedure (Fig. 3.2) 
using two 17G needles. The patient underwent a four-
hour HD treatment without intercurrences. At the end 
a mean hemostasis time of approximately 30 minutes 
was observed. The patient was discharged to the hos-
pital 1 week after surgery, during which dialysis therapy, 
namely ultrafiltration, was optimized. She maintained 
oral anticoagulation. Given the particular characteristics 
of the VA, the patient continued treatment in the HD 
unit of our hospital. She was treated with 12h of dialysis 
per week with mean Kt/V of 1.2, blood flow of 250-300 
ml/min, an arterial pressure ranging from -70 to -50 
mmHg and venous pressure ranging from 200 to 250 
mmHg. Her height was 150 cm and dry weight was 
44Kg, which permitted three treatments per week. 
Two months after the procedure the patient was 
admitted with septic shock secondary to left lower limb 
cellulitis, and died in this context .
 DISCUSSION
With the improved life expectancy of HD patients, 
we are confronted with patients who have exhausted 
their possible venous sites for AVF creation and arte-
riovenous graft (AVG) or even CVC placement. 
In this article, the authors report the case of a young 
woman with APS, with multiple failure of autologous 
VA in the upper limbs due to thrombosis. In addition 
to the depletion of superficial and deep venous capital 
in the upper limbs, the construction of any access at 
this location was compromised due to occlusion of the 
superior and inferior vena cava. Although attempting 
to construct an AVF at the lower limb level was feasible, 
the likelihood of thrombosis was extremely high.
Whilst in 2010 the possibility of constructing this 
type of AV existed, the practices and access policy at 
that time were quite sparse and different from those 
currently implemented. Even for urgent situations, the 
response time was very long; at that time the only 
solution found was a CVC placement.
The sites available for catheter placement are finite 
and should be used sparingly. As we saw with this case, 
complications associated with long-dwelling catheters 
are frequent and inevitably lead to venous patrimony 
losses through time. In the femoral site we used the 
50cm long-term catheter Cannon II from Arrow with 15Fr. 
However, since the patient had a severe infectious com-
plication in her last right femoral CVC and a complete 
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Figure 3
Fig. 3.1: AAG placement; Fig. 3.2: First cannulation of the AAG
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obstruction of the inferior vena cava was observed, the 
possibility of a successful introduction of a new femoral 
CVC was excluded. 
Although stenosis and thrombosis of central veins can 
be treated by angioplasty or surgically, these procedures 
require a suitable jugular vein or a patent contralateral 
venous outflow. Previous studies have demonstrated 
that treatment of central venous occlusions by angio-
plasty shows an excellent initial result, but 1-year primary 
patency rates are ≤ 50%; restenosis rates are high, and 
long-term results are uncertain4-10. Given the severe 
AFS and all the previous thrombosis under anticoagula-
tion, neither angiographic or surgical treatment of the 
central venous occlusions were performed. In order to 
preserve the venous entry site, the catheter exchange 
could be made through a guidewire, using, for example, 
a CVC with a reduced lumen CVC. However, in this case, 
given all the serious infectious complications, this pos-
sibility was not considered. We tried a recanalization, 
through a CVC placement, but it was not successful. It 
was possible to place the CVC in the right atrium by 
collaterality but the Qb was not adequate for HD.
In patients who have exhausted all possible conven-
tional means for an autologous VA, an AAG can be the 
only other option for hemodialysis. In fact, the use of 
an artery as permanent vascular access for HD is not 
a new procedure.
The AAG was first described by Butt and Kountz in 
197611. They reported good results with a femoropopliteal 
graft employed in seven patients in whom a conventional 
VA for HD was not possible. Since that time, a total of 
eight main retrospective studies were published between 
1976 and 2017, reporting data of 151 patients12. Primary 
patency rate ranged from 67%-94.5% at six months to 
54%-61% at 36 months; secondary patency rates from 
83%-93% at six months to 72%-87% at 36 months12. 
The main indication for the AAG is inappropriate 
venous capital, such as absence of superficial venous 
capital, absence of deep veins surgically accessible and 
obstructive central venous disease (intractable or recur-
rent). Other indications for AAG that can be considered 
are the risk of developing cardiac heart failure or high 
risk of critical ischaemia of the extremity with other VA. 
AAG can be placed in three main regions: axillary, brachial 
and femoral. The axillary AAG involves the need for general 
anesthesia and their cannulation is worse, particularly in 
women. On the other hand, brachial AAG allows for easier 
cannulation and placement can be made under general or 
local anesthesia. However, it is only possible to use arteries 
with diameter greater  than 4 mm. Femoral AAG allows 
better flow, but has a higher risk of infection. 
Although all studies reported satisfactory haemodi-
alysis, only Bunger at al13 and Zanow et al14 described 
the actual dialysis data. In the first study the blood flow 
ranged between 250 and 300 ml/min and in the second 
272 mL/min for axillary loops and 416 mL/min for femo-
ral loops. In Zanow et al study there was a four-hour 
treatment efficiency. Given the fact that our patient 
had  about 50 Kg, a four-hour treatment three times 
per week had enough efficacy. 
However, two patients required five hours of treat-
ment. The hemostastatic compression ranged between 
10 and 15 minutes14,15 and it was greater than 15 min-
utes in two studies16,17. 
The post-operative management is different according 
to the published studies (Table 1) and there is no consen-
sus about it12. In the published studies, the authors 
approached the anti-coagulation, the first needle punc-
ture and the surveillance differently. In our patient we 
performed the first needle puncture 2 days after the AAG 
construction. She was already with anticoagulation. 
Unfortunately, in our case report the patient’s short fol-
low-up period was the limiting factor in VA monitoring.
One of the main complications associated with the con-
struction of AAG, given the arterial pressures, is the risk 
of development of false aneurysms. In this case, grafts 
with triple layer may confer an advantage. Thromboem-
bolism or pharmacological embolism are also possible 
complications in AAG, so drug administration is contrain-
dicated in this form of vascular access. However, the most 
feared complication identified is distal ischemia associated 
with graft occlusion. Interestingly, in the studies performed 
the manifestations of ischemia were not concordant13,17. 
Nevertheless, Zanow et al noted that thrombosis of the 
femoral AAG required immediate thrombectomy14. Thus, 
it may be reasonable to consider that in femoral AAG, 
thrombosis is associated with a more severe ischemia, so 
revascularization must be immediate. In the AAG of the 
upper limb, ischemia is more tolerable (probably due to 
collateral circulation), so revascularization may be delayed.
Our patient died of septic shock secondary to left 
lower limb cellulitis. Although the possibility of septic 
embolization could be considered, the AAG had no local 
infectious signs and there was an entrance door in the 
outer side of the left leg, making this the most probable 
starting point for the infection. 
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 CONCLUSION
Although there is a lack of evidence on the use of 
AAG, the data obtained from the studies performed is 
encouraging. This is an alternative VA for HD patients 
who have exhausted all their definite access sites which 
can be considered prior to the placement of a CVC as 
their sole remaining VA. However, there is a need for 
a multicenter study with a larger population of patients. 
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Table 1
Postoperative management of arterioarterial grafts (adapted from 12)
Author(s) Anti-coagulation First needle puncture Surveillance
Khafagy et al13 Heparin 2500-3500 IU intra-op then 
warfarin post procedure. INR 1.5-2.5
If ePTFE, 2 weeks post-op, 48 hours 
postop if Flixene graft
Monthly clinical visits, and duplex  every 3 months.
Dupex assess for:
(1) Patency;
(2) Flow velocity;
(3) Impending failing graft assessment.
Lei et al14 Heparin 4000 units once a day for 3-5 
days and then aspirin 300 mg/day
Not before 2 weeks postop Every 3 months.
(1) Graft blood flow mL/min
(2) Urea reduction ratio %
(3) Clinical exam 
(4) Duplex
Bunger et al15 Heparin 3000 units once.
Aspirin or clopidogrel or phenprocou-
mon from 3-5 days postop
Not before 2 weeks postop Every 3 months
Moncef16 – Day 1 postop –
Zanow et al17 Heparin intra-op then warfarin. INR 
2.5-3.0. If warfarin contra-indicated 
- aspirin
300 mg/day.
Not before 2 weeks postop Every 6 months.
(1) Graft blood flow mL/min
(2) Urea reduction ratio %
(3) Kt/V 
(4) Clinical exam 
(5) Duplex
Talaiezadeh and Haghighi18 – 10 days –
Giacchino et al19 – – –
Butt and Kountz20 – 2 weeks –
 
